Wedbush Weighs in on Alexion Pharmaceuticals, Inc.’s Q4 2021 Earnings (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Wedbush dropped their Q4 2021 EPS estimates for Alexion Pharmaceuticals in a report released on Wednesday, May 6th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will earn $2.48 per share for the quarter, down from their prior forecast of $2.65.

A number of other analysts also recently commented on the company. Bank of America downgraded Alexion Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $130.00 to $110.00 in a research report on Thursday, March 5th. Robert W. Baird cut their target price on Alexion Pharmaceuticals from $165.00 to $140.00 and set an “outperform” rating for the company in a research report on Friday, January 31st. William Blair downgraded Alexion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 5th. Cfra cut their target price on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “strong-buy” rating for the company in a research report on Wednesday, May 6th. Finally, Wolfe Research initiated coverage on Alexion Pharmaceuticals in a research report on Thursday, March 12th. They set an “outperform” rating and a $140.00 target price for the company. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $143.67.

Shares of ALXN stock opened at $101.65 on Monday. The stock has a 50 day moving average of $96.96 and a two-hundred day moving average of $102.77. The company has a current ratio of 4.35, a quick ratio of 3.82 and a debt-to-equity ratio of 0.21. Alexion Pharmaceuticals has a 12 month low of $72.67 and a 12 month high of $134.84. The company has a market capitalization of $21.50 billion, a P/E ratio of 9.57, a P/E/G ratio of 0.80 and a beta of 1.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $3.22 EPS for the quarter, topping the Zacks’ consensus estimate of $2.71 by $0.51. Alexion Pharmaceuticals had a return on equity of 21.96% and a net margin of 44.83%. The company had revenue of $1.44 billion during the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter last year, the company earned $2.39 EPS. The company’s quarterly revenue was up 26.7% on a year-over-year basis.

In related news, Director Bros. Advisors Lp Baker acquired 265,298 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was acquired at an average cost of $78.76 per share, with a total value of $20,894,870.48. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.03% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in the stock. Hillsdale Investment Management Inc. grew its stake in shares of Alexion Pharmaceuticals by 2.3% during the first quarter. Hillsdale Investment Management Inc. now owns 4,470 shares of the biopharmaceutical company’s stock worth $401,000 after purchasing an additional 100 shares during the period. United Asset Strategies Inc. lifted its holdings in Alexion Pharmaceuticals by 2.3% during the fourth quarter. United Asset Strategies Inc. now owns 4,585 shares of the biopharmaceutical company’s stock worth $496,000 after acquiring an additional 105 shares in the last quarter. Mutual of America Capital Management LLC lifted its holdings in Alexion Pharmaceuticals by 0.4% during the first quarter. Mutual of America Capital Management LLC now owns 30,160 shares of the biopharmaceutical company’s stock worth $2,708,000 after acquiring an additional 107 shares in the last quarter. Integrated Wealth Concepts LLC lifted its holdings in Alexion Pharmaceuticals by 6.3% during the fourth quarter. Integrated Wealth Concepts LLC now owns 2,367 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 141 shares in the last quarter. Finally, Hills Bank & Trust Co. lifted its holdings in Alexion Pharmaceuticals by 1.1% during the fourth quarter. Hills Bank & Trust Co. now owns 13,017 shares of the biopharmaceutical company’s stock worth $1,408,000 after acquiring an additional 143 shares in the last quarter. 90.88% of the stock is owned by institutional investors and hedge funds.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Recommended Story: What is the Shanghai Stock Exchange Composite Index?

Earnings History and Estimates for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.